'HR Excellence in Research' logo awarded to institutions actively implementing the European Charter and Code for Researchers.
Please note that the job is no longer active!
Neoangiogenesis plays a key role in the pathogenesis of proliferative diabetic retinopathy (PDR). Aim of the treatment of the RDP is to prevent the formation of new vessels or to destroy the existing one. There are currently two different therapeutic approaches that can be used simultaneously or alternately depending on the severity of the pathology: a therapy relies on the use of a laser to destroy the ischemic retinal areas, the other is a drug therapy that provides intra-vitreal injections of antibodies neutralizing anti-VEGF. However the latter approach, in addition to causing side effects to the neuroretina, is not completely resolutive. Recently have been identified numerous other pro-angiogenic molecules released into the extra-cellular (Growth Hormone (GH), Insulin-like growth factor-1 (IGF-1), Angiopoietins, HGF) the presence of which justifies the partial effectiveness of treatment. Hence the need to develop new therapeutic strategies in the broader spectrum.
Please note that the full description may be available in the national language since some job boards have their own publication policy. Thank you for your understanding!
To better plan and organise their stay in a foreign European country, researchers and their families can also benefit of the free and personalised assistance offered by the EURAXESS Services Centres, a network of more than 200 centres located in 40 different European countries.